NeuroOne stock rallies after FDA clears its OneRF system, a minimally invasive solution targeting severe facial pain, scheduled to launch in late 2025.

NeuroOne has obtained 510(k) clearance from the FDA for its OneRF trigeminal nerve ablation system to treat facial pain.

Trigeminal nerve ablation, a minimally invasive procedure, uses RF energy to destroy abnormal tissue and relieve severe, ...

FDA Clearance Further Validates Technology Platform and Offers Alternatives to Pharmaceutical and Invasive Surgical Treatments EDEN PRAIRIE, Minn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical ...

In this week’s edition of InnovationRx, we look at Phil Knight’s big cancer gift, Medallion’s credentialing clearinghouse, a ...

FDA Clearance Further Validates Technology Platform and Offers Alternatives to Pharmaceutical and Invasive Surgical Treatments EDEN PRAIRIE, Minn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical ...

Ronald W. McClurg, CFO, said, "product revenue increased 105% to $1.7 million" and cited "sizable improvements year-over-year ...

NeuroOne Medical Technologies(NASDAQ:NMTC) reported fiscal third quarter 2025 earnings on August 14, 2025, with product revenue up 105% year-over-year to $1.7 million and product gross margins rising ...

Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., Aug. 14, 2025 ...

Technologies has received U.S. Food and Drug Administration, FDA, clearance to market its OneRF Trigeminal Nerve Ablation ...

Jeffrey Scott Cohen - Ladenburg Thalmann & Co. Inc., Research Division ...